Cyclerion Therapeutics, Inc.
CYCN
$2.95
-$0.20-6.35%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -69.03% | -- |
| Gross Profit | -- | -- | -- | 69.03% | -- |
| SG&A Expenses | -4.57% | -36.68% | -41.76% | -16.19% | -41.77% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -4.94% | -27.35% | -51.24% | -25.79% | -50.60% |
| Operating Income | 9.95% | 127.97% | 58.39% | 25.79% | 50.60% |
| Income Before Tax | 7.33% | 131.29% | 87.76% | 26.68% | 51.62% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 7.33% | 131.29% | 87.76% | 26.68% | 51.62% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 7.33% | 131.29% | -109.56% | 68.38% | 77.83% |
| EBIT | 9.95% | 127.97% | 58.39% | 25.79% | 50.60% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 9.57% | 129.84% | -109.21% | 71.25% | 80.65% |
| Normalized Basic EPS | 9.58% | 131.14% | 73.23% | 33.33% | 57.79% |
| EPS Diluted | 9.57% | 129.84% | -109.33% | 71.07% | 80.65% |
| Normalized Diluted EPS | 9.58% | 131.14% | 73.23% | 33.33% | 57.79% |
| Average Basic Shares Outstanding | 2.49% | 8.73% | 3.74% | 9.99% | 14.61% |
| Average Diluted Shares Outstanding | 2.49% | 8.73% | 3.74% | 9.99% | 14.61% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |